Literature DB >> 23963785

TPX2 expression is associated with cell proliferation and patient outcome in esophageal squamous cell carcinoma.

Po-Kuei Hsu1, Hsuan-Yu Chen, Yi-Chen Yeh, Chueh-Chuan Yen, Yu-Chung Wu, Chung-Ping Hsu, Wen-Hu Hsu, Teh-Ying Chou.   

Abstract

BACKGROUND: The molecular and genetic changes underlying esophageal squamous cell carcinoma (ESCC) tumor formation and rapid progression are poorly understood. Using high-throughput data analysis, we examined molecular changes involved in ESCC pathogenesis and investigated their clinical relevance.
METHODS: Five independent microarray datasets were examined for differentially expressed genes and pathways. For validation, mRNA expression in tumor and matched normal tissues from 16 ESCC cases was examined by cDNA microarray, and protein expression in 97 ESCC specimens was investigated using immunohistochemical stains. The association between clinicopathological parameters and the expression of Aurora kinase A (Aurora-A) and TPX2 was analyzed. The impact of TPX2 expression was also assessed in ESCC cancer cells.
RESULTS: AURKA and TPX2, members of the "Role of Ran in mitotic spindle regulation" pathway, were selected for further investigation. Verification by cDNA microarray showed that both genes were overexpressed in tumor tissues, and immunohistochemical staining showed Aurora-A and TPX2 expression in 88.4 and 90.6 % of ESCC specimens, respectively. High TPX2 expression was a significant prognosticator for overall and disease-free survival in univariate analysis and remained an independent prognostic factor in multivariate analysis (HR 1.802, p = 0.037). TPX2 knockdown clones showed inhibited cellular proliferation in growth curve studies and formed fewer colonies in the clonogenic assay.
CONCLUSIONS: Using bioinformatics resources, which were validated by microarray analysis and immunohistochemistry stains, and manipulation of TPX2 expression in ESCC cell lines, we demonstrated that TPX2 expression is associated with cell proliferation and poor prognosis among patients with resected ESCC.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23963785     DOI: 10.1007/s00535-013-0870-6

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  31 in total

1.  Comparison of the 6th and 7th editions of the American Joint Committee on Cancer tumor-node-metastasis staging system in patients with resected esophageal carcinoma.

Authors:  Po-Kuei Hsu; Yu-Chung Wu; Teh-Ying Chou; Chien-Sheng Huang; Wen-Hu Hsu
Journal:  Ann Thorac Surg       Date:  2010-04       Impact factor: 4.330

2.  Expression of targeting protein for Xenopus kinesin-like protein 2 is associated with progression of human malignant astrocytoma.

Authors:  Bin Li; Xiang-Qian Qi; Xin Chen; Xin Huang; Guo-Ying Liu; Huai-Rui Chen; Cheng-Guang Huang; Chun Luo; Yi-Cheng Lu
Journal:  Brain Res       Date:  2010-06-30       Impact factor: 3.252

3.  Gadd45a interacts with aurora-A and inhibits its kinase activity.

Authors:  Shujuan Shao; Yang Wang; Shunqian Jin; Yongmei Song; Xiaoxia Wang; Wenhong Fan; Zhiying Zhao; Ming Fu; Tong Tong; Lijia Dong; Feiyue Fan; Ningzhi Xu; Qimin Zhan
Journal:  J Biol Chem       Date:  2006-06-12       Impact factor: 5.157

4.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

5.  The clinical significance of Aurora-A/STK15/BTAK expression in human esophageal squamous cell carcinoma.

Authors:  Eiji Tanaka; Yosuke Hashimoto; Tetsuo Ito; Tomoyuki Okumura; Takatsugu Kan; Go Watanabe; Masayuki Imamura; Johji Inazawa; Yutaka Shimada
Journal:  Clin Cancer Res       Date:  2005-03-01       Impact factor: 12.531

Review 6.  The Aurora kinase family in cell division and cancer.

Authors:  Gerben Vader; Susanne M A Lens
Journal:  Biochim Biophys Acta       Date:  2008-07-23

7.  Stable knockdown of Aurora-A by vector-based RNA interference in human esophageal squamous cell carcinoma cell line inhibits tumor cell proliferation, invasion and enhances apoptosis.

Authors:  Xiaoxia Wang; Lijia Dong; Jun Xie; Tong Tong; Qimin Zhan
Journal:  Cancer Biol Ther       Date:  2009-10       Impact factor: 4.742

Review 8.  Protein alterations in ESCC and clinical implications: a review.

Authors:  D-C Lin; X-L Du; M-R Wang
Journal:  Dis Esophagus       Date:  2008-06-17       Impact factor: 3.429

9.  Essential roles of mTOR/Akt pathway in Aurora-A cell transformation.

Authors:  Makoto Taga; Eiji Hirooka; Toru Ouchi
Journal:  Int J Biol Sci       Date:  2009-06-19       Impact factor: 6.580

10.  Gene expression analysis of diagnostic biopsies predicts pathological response to neoadjuvant chemoradiotherapy of esophageal cancer.

Authors:  Stephen G Maher; Charles M Gillham; Shane P Duggan; Paul C Smyth; Nicola Miller; Cian Muldoon; Kenneth J O'Byrne; Orla M Sheils; Donal Hollywood; John V Reynolds
Journal:  Ann Surg       Date:  2009-11       Impact factor: 12.969

View more
  25 in total

1.  TPX2 Level Correlates with Hepatocellular Carcinoma Cell Proliferation, Apoptosis, and EMT.

Authors:  Bo Liang; Chunhong Jia; Yu Huang; Hua He; Jialu Li; Hui Liao; Xiao Liu; Xincheng Liu; Xiaochun Bai; Dinghua Yang
Journal:  Dig Dis Sci       Date:  2015-05-30       Impact factor: 3.199

Review 2.  Long Non-coding RNAs With In Vitro and In Vivo Efficacy in Preclinical Models of Esophageal Squamous Cell Carcinoma Which Act by a Non-microRNA Sponging Mechanism.

Authors:  Ulrich H Weidle; Fabian Birzele
Journal:  Cancer Genomics Proteomics       Date:  2022 Jul-Aug       Impact factor: 3.395

3.  Chromosomal aneuploidies and combinational fluorescence in situ hybridization probe panels are useful for predicting prognosis for esophageal squamous cell carcinoma.

Authors:  Jia-Jie Hao; Han-Qing Yao; Guang-Yun Dai; Wei Kang; Xue-Mei Jia; Xin Xu; Yan Cai; Qi-Min Zhan; Gui-Qi Wang; Ming-Rong Wang
Journal:  J Gastroenterol       Date:  2014-05-11       Impact factor: 7.527

Review 4.  TPX2: of spindle assembly, DNA damage response, and cancer.

Authors:  Gernot Neumayer; Camille Belzil; Oliver J Gruss; Minh Dang Nguyen
Journal:  Cell Mol Life Sci       Date:  2014-02-21       Impact factor: 9.261

5.  Overexpressed targeting protein for Xklp2 (TPX2) serves as a promising prognostic marker and therapeutic target for gastric cancer.

Authors:  Bo Liang; Wenjuan Zheng; Lu Fang; Linquan Wu; Fan Zhou; Xiangbao Yin; Xin Yu; Zhenhong Zou
Journal:  Cancer Biol Ther       Date:  2016-06-17       Impact factor: 4.742

6.  FAM83D, a microtubule-associated protein, promotes tumor growth and progression of human gastric cancer.

Authors:  Minlu Huang; Xinjie Ma; Hongpeng Shi; Lei Hu; Zhiyuan Fan; Li Pang; Fan Zhu; Xiao Yang; Wei Xu; Binya Liu; Zhenggang Zhu; Chen Li
Journal:  Oncotarget       Date:  2017-08-10

7.  Targeting TPX2 Suppresses the Tumorigenesis of Hepatocellular Carcinoma Cells Resulting in Arrested Mitotic Phase Progression and Increased Genomic Instability.

Authors:  Chao-Wen Hsu; Yu-Chia Chen; Hsing-Hao Su; Guan-Jin Huang; Chih-Wen Shu; Tony Tong-Lin Wu; Hung-Wei Pan
Journal:  J Cancer       Date:  2017-05-12       Impact factor: 4.207

8.  Identification of prognostic genes in kidney renal clear cell carcinoma by RNA‑seq data analysis.

Authors:  Yanqin Gu; Linfeng Lu; Lingfeng Wu; Hao Chen; Wei Zhu; Yi He
Journal:  Mol Med Rep       Date:  2017-02-13       Impact factor: 2.952

9.  Therapeutic potential of targeting protein for Xklp2 silencing for pancreatic cancer.

Authors:  Tomohiro Miwa; Toshio Kokuryo; Yukihiro Yokoyama; Junpei Yamaguchi; Masato Nagino
Journal:  Cancer Med       Date:  2015-04-27       Impact factor: 4.452

10.  TPX2 is a prognostic marker and contributes to growth and metastasis of human hepatocellular carcinoma.

Authors:  Yuqi Huang; Wenbin Guo; Heping Kan
Journal:  Int J Mol Sci       Date:  2014-10-09       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.